Equities

Dr. Lal PathLabs Ltd

LALPATHLAB:NSI

Dr. Lal PathLabs Ltd

Actions
Health CareMedical Equipment and Services
  • Price (INR)3,091.10
  • Today's Change29.15 / 0.95%
  • Shares traded112.92k
  • 1 Year change+15.04%
  • Beta0.7463
Data delayed at least 15 minutes, as of Nov 25 2024 10:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Dr. Lal PathLabs Limited is an India-based provider of diagnostic and related healthcare tests and services in India. The Company offers patients and healthcare providers a range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Its tests include Pregnancy Test, Full Body Checkups, Covid 19 Test, Heart Test, Kidney Test, Liver Test, CBC Test, Cholesterol Test, Hepatitis B Test, Kidney Function Test, Liver Function Test, Sugar Test, Thyroid Test, Typhoid Test, Uric Acid Test, Vitamin B12 Test and Vitamin D Test. The Company has approximately 280 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore and Mumbai), 5,762 patient service centers (PSCs) and 11,619 pick-up points (PUPs). Its customers include individual patients, hospitals and other healthcare providers and corporate customers.

  • Revenue in INR (TTM)23.46bn
  • Net income in INR4.01bn
  • Incorporated1995
  • Employees4.10k
  • Location
    Dr. Lal PathLabs Ltd12th FloorTower B, SAS Tower, Sector 38, MedicityGURGAON 122001IndiaIND
  • Phone+91 1 243016500
  • Fax+91 1 244234468
  • Websitehttps://www.lalpathlabs.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Yatharth Hospital & Trauma Cre Srvcs Ltd7.74bn1.29bn52.54bn2.19k39.645.6430.536.7915.4415.4492.57108.590.795215.713.583,542,136.0013.2711.2714.1013.7379.4477.7616.6812.307.2086.400.08820.0028.8845.7874.0695.813.69--
Healthcare Global Enterprises Ltd20.39bn570.45m65.27bn6.15k115.577.5726.313.204.054.05145.2461.830.743520.915.923,316,034.002.23-2.263.09-3.0553.2253.783.00-3.500.84191.370.6324--12.8014.3564.08---0.3308--
Jupiter Life Line Hospitals Ltd11.73bn1.85bn99.72bn2.77k54.657.9243.088.5027.8327.83176.26191.930.89519.4420.094,238,544.0014.12--15.75--82.00--15.78--3.1552.160.00--19.83--142.25------
Metropolis Healthcare Ltd12.85bn1.48bn105.71bn4.31k71.668.9241.888.2228.7728.77249.83231.050.81856.7210.002,979,279.009.4713.6511.2316.9478.9175.4311.5614.661.4910.320.137623.525.189.67-10.541.2521.84--
Vijaya Diagnostic Centre Ltd6.27bn1.33bn125.17bn2.05k94.4717.2763.3419.9612.9112.9161.0770.640.611414.8354.303,054,368.0013.0014.1014.4015.5487.7985.5821.2621.202.307.540.2866.6619.2913.3640.4020.977.58--
Sagility India Ltd48.61bn2.08bn131.17bn35.86k63.041.7215.592.700.44450.444510.3816.250.4618--4.871,387,054.001.98--2.21--99.00--4.28----2.790.166--12.69--58.99------
Rainbow Children's Medicare Ltd14.25bn2.32bn160.94bn3.94k69.6711.9844.5411.3022.7522.75139.95132.290.68517.9117.843,616,084.0011.179.8912.0410.9687.4582.9616.3113.804.125.020.3602--10.5119.032.9337.2332.22--
Aster DM Healthcare Ltd16.42bn2.51bn215.29bn14.02k88.876.2755.2813.114.86108.0832.2168.980.14671.201.261,171,811.002.852.244.163.6040.8259.7319.404.261.827.410.3501--23.54-14.2212.28-18.156.87--
Krishna Institute Of Medical Sciencs Ltd27.05bn3.31bn238.18bn5.01k71.9211.9045.318.808.288.2867.5950.030.676510.768.265,396,635.009.1013.7111.3316.7379.3754.2913.4515.530.86788.110.43840.0013.6722.17-7.78--52.94--
Dr. Lal PathLabs Ltd23.46bn4.01bn254.37bn4.10k63.4012.7146.3210.8448.1748.17281.60240.300.930610.5526.725,724,423.0016.1315.4920.1219.3880.2876.1317.3315.992.7720.160.088923.8610.4013.1049.7812.436.4431.95
Narayana Hrudayalaya Ltd52.21bn7.79bn258.38bn11.66k33.178.1124.994.9538.3538.35257.10156.860.946620.969.504,477,685.0014.1310.7918.0813.9760.9247.1114.929.721.467.620.34689.6410.9111.8930.1967.8945.2731.95
Data as of Nov 25 2024. Currency figures normalised to Dr. Lal PathLabs Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

23.63%Per cent of shares held by top holders
HolderShares% Held
Wasatch Advisors LPas of 13 Sep 20244.15m4.96%
Invesco Advisers, Inc.as of 30 Sep 20243.29m3.93%
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Oct 20242.68m3.21%
UTI Asset Management Co. Ltd. (Investment Management)as of 30 Jun 20242.35m2.82%
First Sentier Investors (Australia) IM Ltd.as of 30 Jun 20241.46m1.74%
SBI Funds Management Ltd.as of 31 Oct 20241.45m1.74%
The Vanguard Group, Inc.as of 06 Nov 20241.29m1.55%
Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 20241.23m1.47%
First Sentier Investors (Singapore)as of 30 Jun 2024922.00k1.10%
First Sentier Investors (Hong Kong) Ltd.as of 30 Jun 2024922.00k1.10%
More ▼
Data from 30 Sep 2024 - 19 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.